| Mr Thad David Hardin, M D | |
|
1260 S Palestine St, Athens, TX 75751-3619 | |
| (903) 675-8111 | |
| (903) 675-3888 |
| Full Name | Mr Thad David Hardin |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 31 Years |
| Location | 1260 S Palestine St, Athens, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497758460 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0009X | Ophthalmology - Glaucoma Specialist | L0248 (Texas) | Secondary |
| 207W00000X | Ophthalmology | L0248 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ut Health East Texas Athens Hospital | Athens, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charles L. Heaton , M.d. P.a. | 1557257615 | 15 |
News Archive
Ethnic differences in appointment keeping may be an important factor in poor health outcomes among some minority patients with diabetes, according to a new study.
Patients with dementia and diabetes appear to display a different pattern of injuries in their brains than patients with dementia but without diabetes, according to an article posted online today that will appear in the March print issue of Archives of Neurology.
An emerging technology involving tiny particles that absorb light and turn it into localized heat sources shows great promise in several fields, including medicine.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
› Verified 4 days ago
| Entity Name | Charles L. Heaton , M.d. P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528127172 PECOS PAC ID: 1557257615 Enrollment ID: O20040225000598 |
News Archive
Ethnic differences in appointment keeping may be an important factor in poor health outcomes among some minority patients with diabetes, according to a new study.
Patients with dementia and diabetes appear to display a different pattern of injuries in their brains than patients with dementia but without diabetes, according to an article posted online today that will appear in the March print issue of Archives of Neurology.
An emerging technology involving tiny particles that absorb light and turn it into localized heat sources shows great promise in several fields, including medicine.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Thad David Hardin, M D 3415 Golden Rd, Tyler, TX 75701-8355 Ph: (903) 526-0444 | Mr Thad David Hardin, M D 1260 S Palestine St, Athens, TX 75751-3619 Ph: (903) 675-8111 |
News Archive
Ethnic differences in appointment keeping may be an important factor in poor health outcomes among some minority patients with diabetes, according to a new study.
Patients with dementia and diabetes appear to display a different pattern of injuries in their brains than patients with dementia but without diabetes, according to an article posted online today that will appear in the March print issue of Archives of Neurology.
An emerging technology involving tiny particles that absorb light and turn it into localized heat sources shows great promise in several fields, including medicine.
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
› Verified 4 days ago
Dr. Robert Joseph Nettune, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5773 Impala South Road, Athens, TX 75752 Phone: 903-681-4840 | |
Dr. Pamela Christine Carter, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1240 S Palestine St, Athens, TX 75751 Phone: 903-575-8111 Fax: 903-595-6650 |